- Home
- LXEO vs DMAC Comparison
LXEO vs DMAC Comparison
Compare LXEO & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEO
- DMAC
- Stock Information
- Founded
- LXEO 2017
- DMAC 2000
- Country
- LXEO United States
- DMAC United States
- Employees
- LXEO N/A
- DMAC N/A
- Industry
- LXEO
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- LXEO
- DMAC Health Care
- Exchange
- LXEO Nasdaq
- DMAC Nasdaq
- Market Cap
- LXEO 252.4M
- DMAC 274.1M
- IPO Year
- LXEO 2023
- DMAC N/A
- Fundamental
- Price
- LXEO $6.14
- DMAC $4.82
- Analyst Decision
- LXEO Strong Buy
- DMAC Strong Buy
- Analyst Count
- LXEO 5
- DMAC 3
- Target Price
- LXEO $23.80
- DMAC $7.00
- AVG Volume (30 Days)
- LXEO 274.8K
- DMAC 118.6K
- Earning Date
- LXEO 12-31-2024
- DMAC 11-13-2024
- Dividend Yield
- LXEO N/A
- DMAC N/A
- EPS Growth
- LXEO N/A
- DMAC N/A
- EPS
- LXEO N/A
- DMAC N/A
- Revenue
- LXEO N/A
- DMAC N/A
- Revenue This Year
- LXEO N/A
- DMAC N/A
- Revenue Next Year
- LXEO N/A
- DMAC N/A
- P/E Ratio
- LXEO N/A
- DMAC N/A
- Revenue Growth
- LXEO N/A
- DMAC N/A
- 52 Week Low
- LXEO $5.77
- DMAC $2.14
- 52 Week High
- LXEO $22.33
- DMAC $6.41
- Technical
- Relative Strength Index (RSI)
- LXEO 35.77
- DMAC 47.28
- Support Level
- LXEO $6.78
- DMAC $5.05
- Resistance Level
- LXEO $7.40
- DMAC $5.74
- Average True Range (ATR)
- LXEO 0.66
- DMAC 0.37
- MACD
- LXEO -0.13
- DMAC -0.08
- Stochastic Oscillator
- LXEO 1.34
- DMAC 28.10
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.